ALK and adenocarcinoma: New treatments, mainly including bevacizumab, anaplastic lymphoma kinase (ALK) inhibitors, and EGFR tyrosine kinase inhibitors, have significantly improved the overall survival of patients with adenocarcinoma, but the therapeutic effects are not effective for lung SCC patients (7,8).